当前位置： SCI文献检索 > THROMBOSIS RESEARCH期刊下所有文献 > Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

Abstract：

BACKGROUND:The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer. MATERIAL AND METHODS:We studied 104 women with breast carcinoma (patient group) and 104 healthy age-matched women (control group). In patients and controls, the PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA. RESULTS:The frequency of the PAI-1 4G allele tended to be higher in patients than in controls (p=0.062). The presence of the 4G allele (4G/5G plus 4G/4G genotypes) was significantly higher among patients with histological grade 3 tumors than among those with grade 1 tumors (p=0.026). Furthermore, patients with the 4G/4G genotype had significantly higher tissue PAI-1 levels than those with the 5G/5G genotype. Moreover, tissue PAI-1 antigen levels were significantly and positively correlated with tumor severity (p=0.003) and tumor size (p=0.009). However, no significant differences in PAI-1 level were observed in relation to menopause, hormone receptor or nodal status. CONCLUSION:Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Castelló R,España F,Vázquez C,Fuster C,Almenar SM,Aznar J,Estellés A

doi

10.1016/j.thromres.2005.03.025

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

487-92

issue

5

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(05)00139-8

journal_volume

117

pub_type

杂志文章

相关文献

THROMBOSIS RESEARCH文献大全
  • Use of purified dermatan sulfate for heparin cofactor II (HC II) assay.

    abstract：:HC II functional assays are generally preferred with respect to immunochemical assays. Nevertheless functional assays can be biased by the antithrombin III (AT III)-heparin complex activity; in fact trace amounts of heparin generally contaminate dermatan sulfate (DS) commercial preparations used as HC II reaction acti...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(92)90248-9

    authors： Ruzzenente O,Ghidini R,Poli G,Schiavon R,Guidi GC

    更新日期：1992-01-15 00:00:00

  • Frequency of use and acceptability of clinical prediction rules for pulmonary embolism among Swiss general internal medicine residents.

    abstract：INTRODUCTION:Whether clinical prediction rules for pulmonary embolism are accepted and used among general internal medicine residents remains uncertain. We therefore evaluated the frequency of use and acceptability of the Revised Geneva Score (RGS) and the Pulmonary Embolism Severity Index (PESI), and explored which fa...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2017.09.028

    authors： Faller N,Stalder O,Limacher A,Bassetti S,Beer JH,Genné D,Battegay E,Hayoz D,Leuppi J,Mueller B,Perrier A,Waeber G,Rodondi N,Aujesky D

    更新日期：2017-12-01 00:00:00

  • Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.

    abstract：:Patients with active cancer have a heightened risk of venous thromboembolism (VTE). This risk is further increased by the initiation of chemotherapy. Although previous studies have suggested that the use of parenteral thromboprophylaxis in all ambulatory cancer patients receiving chemotherapy significantly decreases t...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2018.01.018

    authors： Kimpton M,Wells PS,Carrier M

    更新日期：2018-04-01 00:00:00

  • Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator.

    abstract：:Heparinase degraded heparin fragments (HDHF) are enriched with a UV chromophore and can be utilized as calibrators to determine the molecular weight profile of low molecular weight heparins (LMWH's). In a standard protocol (1), the second to the last peak is assumed to be a hexasaccharide with a molecular weight of 1....

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(93)90222-a

    authors： Jeske W,Ahsan A,Fareed J

    更新日期：1993-04-01 00:00:00

  • Hemorrhagic and thrombotic complications in bone marrow transplant recipients.

    abstract：:Hemostatic challenges occur throughout the period of stem cell transplantation (SCT). Endothelial cells injury due to chemotherapy, growth factors, intravenous catheter, and graft-versus-host disease and profound thrombocytopenia are the major components involved in the hemostatic complications. Diffuse alveolar hemor...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/S0049-3848(07)70136-6

    authors： Nadir Y,Brenner B

    更新日期：2007-01-01 00:00:00

  • Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation.

    abstract：:Severe bleeding took place in a patient when abdominal aneurysm was removed by operation. Bleeding continued after infusion of heparin, antithrombin III (ATIII), fresh platelets and fresh blood. Infusion of tranexamic acid resulted in an immediate cessation of bleeding and improvement of his general condition. Sometim...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(90)90167-b

    authors： Takada A,Takada Y,Mori T,Sakaguchi S

    更新日期：1990-04-15 00:00:00

  • Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: Thromboelastometry versus routine coagulation testing.

    abstract：INTRODUCTION:Bivalirudin is an alternative to heparin anticoagulation in infants and children in the setting of extracorporeal life support (ECLS). While activated partial thromboplastin time (aPTT) is widely accepted as the standard test to monitor bivalirudin therapy, the usefulness of thromboelastometry (ROTEM) to m...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2019.12.007

    authors： Teruya J,Hensch L,Bruzdoski K,Adachi I,Hui SR,Kostousov V

    更新日期：2020-02-01 00:00:00

  • Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

    abstract：BACKGROUND:Although patients undergoing coronary stenting routinely receive dual antiplatelet treatment to reduce the risk of stent thrombosis, this undesired event still occurs. A suboptimal response to clopidogrel treatment (low responders) has been suggested to contribute to stent thrombosis. In the present study, p...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2004.07.007

    authors： Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,Ramírez C,Barrera-Ramirez C,Sabaté M,Hernández R,Moreno R,Escaned J,Alfonso F,Bañuelos C,Costa MA,Bass TA,Macaya C

    更新日期：2005-01-01 00:00:00

  • Splice variants of Tissue Factor and integrin-mediated signaling.

    abstract：:Full-length Tissue Factor (flTF) - the obligatory co-factor for the serine protease (factor) VII/VIIa - serves as the initiator of blood coagulation. The flTF/VIIa complex triggers a sequence of proteolytic events that lead to the formation of a hemostatic plug. Aside from hemostatic maintenance, flTF can contribute t...

    journal_title：Thrombosis research

    pub_type： 杂志文章,评审

    doi：10.1016/j.thromres.2012.02.027

    authors： Srinivasan R,Bogdanov VY

    更新日期：2012-05-01 00:00:00

  • Differential labeling of platelet alpha 2 adrenoceptors by 3H dihydroergocryptine and 3H yohimbine in patients with myeloproliferative disorders.

    abstract：:Platelet alpha adrenoceptor status was examined using the radioligands 3H-yohimbine (3H-YOH) and 3H-dihydroergocryptine (3H-DHE) in 14 patients with myeloproliferative disorder (MPD) and 10 normal controls. Platelets from normal controls and MPD patients sensitive to adrenaline induced aggregation exhibited approximat...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(85)90300-7

    authors： Swart SS,Wood JK,Barnett DB

    更新日期：1985-12-01 00:00:00

  • Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.

    abstract：:Time response curves of the anti-thrombotic effects, bleeding enhancing effects, effects on APTT, anti-Xa activities, anti-thrombin activities and thrombin generation inhibitory activities of the low molecular weight heparinoid Org 10172 and heparin have been compared in rats. The time courses of these effects were si...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(87)90386-0

    authors： Hobbelen PM,Vogel GM,Meuleman DG

    更新日期：1987-12-01 00:00:00

  • Evaluation of annexin V as a platelet-directed thrombus targeting agent.

    abstract：:Annexin V is a human phospholipid binding protein (M(r) 36,000) that binds with high affinity to activated platelets in vitro. We studied the biodistribution and thrombus binding of annexin V in rabbit and swine models of fully occlusive arterial thrombi formed 1-2 h prior to injection of annexin V. Iodinated annexin ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(94)90224-0

    authors： Tait JF,Cerqueira MD,Dewhurst TA,Fujikawa K,Ritchie JL,Stratton JR

    更新日期：1994-09-01 00:00:00

  • Blood coagulation and fibrinolysis after extreme short-term exercise.

    abstract：INTRODUCTION:Maximal exercise may be a trigger for cardiovascular events. The aim of the study was to investigate changes in blood coagulation and fibrinolysis following maximal short-term exercises with different durations up to 90 s. METHODS:A total of 15 healthy nonsmokers underwent three isokinetic maximal tests o...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/s0049-3848(03)00283-4

    authors： Hilberg T,Prasa D,Stürzebecher J,Gläser D,Schneider K,Gabriel HH

    更新日期：2003-03-15 00:00:00

  • The novel P2Y 12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats.

    abstract：INTRODUCTION:Excessive platelet activation fundamentally contributes to cardiovascular events and mortality in patients with diabetes mellitus. Functional resistance has been described for current antiplatelet therapies in broad populations that include patients with diabetes. We investigated acute and chronic effects ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2009.09.025

    authors： Flierl U,Schöpp C,Jaitner J,Bauersachs J,Schäfer A

    更新日期：2010-03-01 00:00:00

  • Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study.

    abstract：:In a double-blind, placebo-controlled trial of 40 patients requiring aortocoronary vene transplant surgery, prostacyclin (PGI2) was infused in a dose of 8 ng/kg/min throughout cardiopulmonary bypass. When compared with the placebo-group, the patients treated with PGI2 were found to have significantly higher platelet c...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(83)90093-2

    authors： Heinrich D,Schleussner E,Wagner WL,Sellmann-Richter R,Hehrlein FW

    更新日期：1983-11-15 00:00:00

  • Aggregated-disaggregated, refractory platelets retain sensitivity to ristocetin.

    abstract：:The present investigation has used an aggregation-disaggregation-reaggregation model to determine if exposure to potent aggregating agents causing a refractory state in deaggregated platelets results in down-regulation and clearance of GPIb/IX, the receptor for von willebrand factor. Thrombin, the thrombin receptor ac...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/s0049-3848(96)00185-5

    authors： White JG,Rao GH

    更新日期：1996-11-15 00:00:00

  • Anti- and procoagulant activities in factor VII-deficient subjects.

    abstract：:The clinical feature in patients with congenital factor VII deficiency is in part dependent on the underlying genetic defect, but the mechanisms influencing the genotype-phenotype correlation remain to be fully elucidated. In addition, thromboembolic events have been reported. Compensatory mechanisms involving vitamin...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/s0049-3848(00)00410-2

    authors： Astermark J,Tengborn L,Hedner U,Berntorp E

    更新日期：2001-03-15 00:00:00

  • The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor.

    abstract：OBJECTIVES:Elevated plasma homocysteine has been implicated as a risk factor for hypertension. C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction. Angiotensin-converting enzyme (ACE) inhibitors appear to remedy ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2004.04.005

    authors： Jiang S,Hsu YH,Xu X,Xing H,Chen C,Niu T,Zhang Y,Peng S,Xu X

    更新日期：2004-01-01 00:00:00

  • Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.

    abstract：:The specific thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 13-azaprostanoic acid (13-APA) reverses platelet aggregation stimulated by TXA2/PGH2 and the prostaglandin endoperoxide analog U46619. The present report demonstrates that the deaggregatory properties of 13-APA are potentiated by prostacyclin (PGI2). ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(82)90097-4

    authors： Parise LV,Venton DL,Le Breton GC

    更新日期：1982-12-15 00:00:00

  • Comparison of the in vitro effect of eicosapentaenoic acid (EPA)-derived lipoxygenase metabolites on human platelet function with those of arachidonic acid.

    abstract：:Eicosapentaenoic acid (EPA) has been reported to have a potent anti-aggregatory activity and to be efficiently metabolized by 12-lipoxygenase, not by cyclooxygenase in platelets. In vitro effect of 12-lipoxygenase metabolites of EPA on platelet function was studied and compared with those of arachidonic acid (AA). The...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(86)90248-3

    authors： Takenaga M,Hirai A,Terano T,Tamura Y,Kitagawa H,Yoshida S

    更新日期：1986-02-01 00:00:00

  • Changes in thrombomodulin level in plasma of endotoxin-infused rabbits.

    abstract：:Changes in the plasma thrombomodulin (TM) level were examined in endotoxin-infused rabbits. The plasma TM level in normal rabbits was 143.8 +/- 8.4 ng/ml (n = 67) and the molecular weight of the major TM was about 55 kd. Endotoxin (lipopolysaccharide, LPS, E. Coli B8:0127) was intravenously infused. LPS infusion incre...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(92)90240-b

    authors： Sawada K,Yamamoto H,Matsumoto K,Yago H,Suehiro S,Tahara C,Ishii H,Kazama M,Abe T

    更新日期：1992-01-15 00:00:00

  • Point-of-care antithrombotic monitoring in children.

    abstract：INTRODUCTION:The use of oral anticoagulant therapy is increasing in children. Managing anticoagulant therapy in children presents unique challenges, including poor venous access. The advent of point-of-care (POC) monitoring of anticoagulant therapy offers a potential solution to this challenge. This paper reviews the p...

    journal_title：Thrombosis research

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.thromres.2005.03.008

    authors： Newall F,Bauman M

    更新日期：2006-01-01 00:00:00

  • The action of thrombin on peptide p-nitroanilide substrates: hydrolysis of Tos-Gly-Pro-Arg-pNA and D-Phe-Pip-Arg-pNA by human alpha and gamma and bovine alpha and beta-thrombins.

    abstract：:Human and bovine alpha-thrombins (greater than 90% alpha form) with high fibrinogen clotting activities (approximately 3,000 U.S. units/mg protein) exhibit similar Michaelis menten kinetics with the p-nitroanilide tripeptide substrates Tos-Gly-Pro-arg-pNA (Chromozym-TH) and D-Phe-Pip-Arg-pNA (S-2238). The kinetic para...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(82)90114-1

    authors： Lottenberg R,Hall JA,Fenton JW 2nd,Jackson CM

    更新日期：1982-11-01 00:00:00

  • Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.

    abstract：:A synthetic pentasaccharide, representing the critical sequence required in heparin for binding to antithrombin III (AT III), produces strong anti-factor Xa activity in vitro in the presence of AT III and is devoid of any activity directed towards thrombin. This pentasaccharide provides a unique tool to study the ques...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(87)90280-5

    authors： Walenga JM,Petitou M,Lormeau JC,Samama M,Fareed J,Choay J

    更新日期：1987-04-15 00:00:00

  • Prevention of VTE in women with cancer.

    abstract：:The prevention of venous thromboembolism (VTE) in women with cancer requires special consideration. The presence of cancer results in both non-surgical and surgical patients having increased risk of VTE. This usually leads to a modification of the recommended preventive therapy, affecting the type, dose and length of ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/S0049-3848(11)70003-2

    authors： Cohen AT,Wills JO,Bharathi N,Solis JV

    更新日期：2011-02-01 00:00:00

  • Rho-kinase inhibitor treatment prevents pulmonary inflammation and coagulation in lipopolysaccharide-induced lung injury.

    abstract：INTRODUCTION:In the pathogenesis of sepsis-induced acute lung injury (ALI), the crosstalk between inflammation and coagulation plays a pivotal role. The aim of this study was to investigate the role of Rho kinase (ROCK) inhibitor in alleviating pulmonary inflammation and coagulation in lipopolysaccharide (LPS)-induced ...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/j.thromres.2016.12.020

    authors： Ding R,Zhao D,Li X,Liu B,Ma X

    更新日期：2017-02-01 00:00:00

  • Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin.

    abstract：:The lupus ratio (LR) test is a normalized ratio of the clotting times obtained with low and high phospholipid (PL) concentrations, where the test plasma is mixed 1:1 with normal pooled plasma (NP). As an integrated, automated, and computer-assisted assay, this principle has been applied to the dilute activated partial...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/s0049-3848(01)00420-0

    authors： Liestøl S,Jacobsen EM,Wisløff F

    更新日期：2002-01-15 00:00:00

  • Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X.

    abstract：:We purified the urinary procoagulant from frozen human urine by introducing phenyl-Sepharose hydrophobic chromatography. By this method, the apoprotein of the procoagulant and the lipid-like substance were separately recovered. Upon reassociation with the lipid-like substance or exogenous crude phospholipids, the apop...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(84)90114-2

    authors： Kurosawa S,Matsuda M,Aoki N

    更新日期：1984-03-15 00:00:00

  • The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.

    abstract：:A new method, based on the observation that leukocytes contain PGI2-synthetase activity, was used to measure the effect of pharmacological levels of sulphinpyrazone on the TXA2 and PGI2 production in whole blood. Four human volunteers took 400 mg sulphinpyrazone twice daily for 5 1/2 days. Blood was drawn before the s...

    journal_title：Thrombosis research

    pub_type： 杂志文章

    doi：10.1016/0049-3848(82)90033-0

    authors： Badenhorst PN,Deckmyn H,Vermylen J

    更新日期：1982-10-01 00:00:00

  • Old and new heparins.

    abstract：:Heparin is an effective, relatively safe, inexpensive parenteral antithrombotic agent widely used in the prevention and treatment of thromboembolic disorders, but it has several limitations such as the marked intra- and inter-patient variability in its anticoagulant response, its poor bioavailability at low doses and ...

    journal_title：Thrombosis research

    pub_type： 杂志文章,评审

    doi：10.1016/j.thromres.2011.11.008

    authors： Cosmi B,Palareti G

    更新日期：2012-03-01 00:00:00